May 1 |
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
Apr 30 |
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
|
Apr 29 |
Merck late-stage data strengthens profile of pneumonia vaccine candidate
|
Apr 29 |
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
|
Apr 29 |
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
|
Apr 27 |
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
|
Apr 26 |
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
|
Apr 25 |
Merck (MRK) Q1 2024 Earnings Call Transcript
|
Apr 25 |
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
|
Apr 25 |
Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript
|